Direct oral anticoagulants for the treatment of cerebral venous thrombosis – a protocol of an international phase IV study

IntroductionCurrent guidelines recommend that patients with cerebral venous thrombosis (CVT) should be treated with vitamin K antagonists (VKAs) for 3–12 months. Direct oral anticoagulants (DOACs), however, are increasingly used in clinical practice. An exploratory randomized controlled trial includ...

全面介紹

書目詳細資料

發表在:	Frontiers in Neurology
Main Authors:	Anita van de Munckhof, Mayte Sánchez van Kammen, Katarzyna Krzywicka, Sanjith Aaron, Diana Aguiar de Sousa, Florina Antochi, Antonio Arauz, Miguel A. Barboza, Adriana B. Conforto, Francesco Dentali, Daniel Galdames Contreras, Xunming Ji, Katarina Jood, Mirjam R. Heldner, María Hernández-Pérez, Wayneho Kam, Timothy J. Kleinig, Espen S. Kristoffersen, Ronen R. Leker, Robin Lemmens, Sven Poli, Nilüfer Yeşilot, Mohammad Wasay, Teddy Y. Wu, Marcel Arnold, Lia Lucas-Neto, Saskia Middeldorp, Jukka Putaala, Turgut Tatlisumak, José M. Ferro, Jonathan M. Coutinho
格式:	Article
語言:	英语
出版:	Frontiers Media S.A. 2023-09-01
主題:	cerebral venous thrombosis anticoagulants DOAC vitamin K antagonist treatment
在線閱讀:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1251581/full